An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Subjects With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With Gemcitabine or Gemcitabine+Nab-paclitaxel Chemotherapies
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 8
- 主要终点
- Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0
研究概览
简要总结
To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.
The clinical investigation will be conducted at approximately 5 sites in the United States involving 20 patients.
详细描述
The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil™, when implanted into patients with pancreatic cancer, in conjunction with Standard chemotherapy. OncoSil™, is an experimental treatment and carries the active treatment "radioactive Phosphorous (32P)" inside inactive silicon particles. Once implanted, the OncoSil™ Microparticles will stay in the tumour permanently. The purpose of OncoSil™, is to deliver the action of 32P directly into a targeted tumour to destroy cancer cells.
20 Patients will be taking part in a single arm open label research study - which means that everyone in the research study will receive the investigational treatment OncoSil™, plus their prescribed standard chemotherapy regimen which will be either Gemcitabine or Gemcitabine + nab-paclitaxel (Abraxane).
Endpoints: Primary Endpoint:
• Safety and Tolerability
Secondary Endpoints:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven adenocarcinoma of the pancreas.
- •Stage III unresectable locally advanced pancreatic carcinoma. Patients with technically resectable tumors (T1-T3) will also be eligible, if they are deemed unresectable due to medical comorbidities or refusal of surgery.
- •Pancreatic target tumor diameter of ≥ 2.0 cm (shortest axis) to ≤ 6.0 cm (longest axis), as qualified by the central reading center.
- •An ECOG Performance Status of 0 to 1 and Karnofsky Performance Status of 80 -
- •Study participants' ≥ 18 years of age at screening.
- •To commence first-line standard gemcitabine and nab-paclitaxel chemotherapy, or gemcitabine alone, (per standard of care (SoC) according to the approved prescribing schedule), within 14 days post enrollment, with OncoSil™ implantation to occur during the fourth (4th) week of the first chemotherapy cycle.
- •Provide signed Informed Consent.
- •Willing and able to complete study procedures within the study timelines.
- •Adequate renal function: serum creatinine less than 1.5 x upper limit of normal (ULN).
- •Adequate liver function: serum liver transaminases ≤ 3 × ULN and serum bilirubin ≤ 1.5 × ULN*.
- •* For study participants with recent biliary obstruction treated by drainage (e.g. stent), serum bilirubin of > 1.5 x ULN will be accepted for study entry provided that serial levels demonstrate clear improvement. In addition, chemotherapy should not be commenced until serum bilirubin is ≤ 1.5 × ULN.
- •Adequate bone marrow function: white blood cells (WBCs) ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, hemoglobin ≥ 9 g/dL, and platelets ≥ 100,000/mm
- •Life expectancy of at least 3 months at the time of screening as judged by the investigator.
- •Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least 6 months post implantation.
- •Not pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and 12 months post implantation of the investigational device.
排除标准
- •Evidence of distant metastases, based on review of baseline CT scan, as determined by the central reading center.
- •More than one primary lesion.
- •Any prior radiotherapy or chemotherapy for pancreatic cancer.
- •Use of other investigational agent at the time of screening, or within 30 days or five half-lives of Screening Visit 1, whichever is longer.
- •Pregnant or lactating.
- •In the opinion of the investigator, EUS directed implantation posing undue study participant risk. This includes:
- •where previous EUS-FNA was considered technically too difficult to perform;
- •imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumor within the pancreas;
- •presence (or significant risk) of varices near to the target tumor. Note: The feasibility of implantation of the target tumor and assessment of risk can be conducted at any time between Screening Visit 1 and the implantation date. A study participant should be considered for withdrawal prior to and including at the time of OncoSil™ treatment, if any of the above risk features become apparent following study participant screening and/or enrolment.
- •History of malignancy, treated or untreated, within the past five years whether or not there is evidence of local recurrence or metastases, with the exception of basal cell carcinoma of the skin and cervical carcinoma in situ.
- •Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).
- •A known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components.
- •Any other health condition that would preclude participation in the study in the judgement of the investigator.
结局指标
主要结局
Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0
时间窗: Collected from the of signed informed consent until patient death or 104 weeks post last patient enrollment date, whichever is sooner]
as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0
次要结局
- Local Progression free survival within the pancreas(Assessed from Baseline through to first confirmed CT documentation of local progression within the pancreas, an average of 12 months)
- Overall survival(Assessed from Baseline to 104 weeks post last patient first study visit])
- Body weight(Assessed from Baseline through to EOS visit, an average of 12 months)
- Impaired function(Measured at each study visit for the duration of the study, an average of 12 months)
- Progression free survival - entire body(Assessed from Baseline through to EOS visit - an average of 12 months)
- Pain Scores(Measured at each study visit for the duration of the study, an average of 12 months)